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Background: The treatment of central diabetes insipidus (DI) with desmopressin in the neonatal period is challenging
because of the significant risk of hyponatremia with this agent. The fixed anti-diuresis action of desmopressin and the
obligate high fluid intake with milk feeds lead to considerable risk of water intoxication and hyponatremia. To reduce
this risk, thiazide diuretics, part of the treatment of nephrogenic DI, were used in conjunction with low renal solute feed
and were effective in a single case series of neonatal central DI.
Aim: We evaluated the efficacy of early treatment of neonatal central DI with hydrochlorothiazide with low solute
feed and investigated the clinical indicators for transition to desmopressin during infancy.
Methods: A retrospective chart review was conducted at Princess Margaret Hospital, Perth of neonates diagnosed with
central DI and treated with hydrochlorothiazide, between 2007 and 2013. Four newborns were identified. Mean sNa
and mean change in sNa with desmopressin and hydrochlorothiazide treatment were recorded along with episodes
of hyponatremia and hypernatremia. Length and weight trajectories during the first 12 months were assessed.
Results: The mean change in sNa per day with hydrochlorothiazide and low renal solute feed was 2.5 - 3 mmol/L; on
desmopressin treatment, the mean change in sNa was 6.8-7.9 mmol/L. There was one episode of symptomatic
hyponatremia with intranasal desmopressin with no episodes of hyponatremia or hypernatremia during treatment
with hydrochlorothiazide or following transition to oral desmopressin. Transition to oral desmopressin between 3
to 12 months of age was associated with good control of DI. Following introduction of solids, sNa remained stable
but weight gain was slow. This improved following transition to desmopressin in one infant.
Conclusions: Hydrochlorothiazide with low renal solute feed is a safe and effective treatment option in neonatal
central DI. However, transition to desmopressin should be considered early in infancy following initiation of solids
to facilitate growth.
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Nan®HA: commercially available formula.
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Central Diabetes Insipidus (DI) in newborns and infants is
due to the deficiency of arginine vasopressin (AVP) from
the posterior pituitary and is associated with septo-optic
dysplasia and other midline malformations [1]. DI should
be considered in polyuric neonates with elevated serum
sodium and osmolality and an inappropriately low urine
osmolality (<300 mosm/kg). Polyuria is characterized by a
urine volume in excess of 2 l/m2/24 h or approximately
150 ml/kg/24 h at birth [2]. Desmopressin acetate (1-
deamino-8-D arginine vasopressin) is the long acting
synthetic analogue of vasopressin, without its vasocon-
strictive effect, and is the current therapeutic agent of
choice in the management of patients with central DI [1].
It binds to the V2 vasopressin receptor on the distal
tubules and collecting ducts of the kidney to increase
water reabsorption.
Desmopressin is available in oral, nasal and parental
preparations and there is a high degree of dose variability
between the different forms. In general, the oral dose is
about ten times greater than the intranasal dose while the
SC dose is 10 times more potent than the intranasal dose
[3]. There is also marked inter-individual differences in
sensitivity to the drug. These factors make establishing the
correct dose and frequency of administration difficult.
The fixed anti-diuresis action of desmopressin and the
high fluid intake necessary to meet caloric requirements
of newborns with milk feeds [4] increase the risk of hypo-
natremia and make the management of newborns with
central DI challenging and difficult.
Thiazide diuretics are used in nephrogenic DI and
have been used effectively in a case series of 3 newborns
with central DI when desmopressin treatment caused
varying sNa levels [5]. The principal action of thiazide
diuretics is at the distal convoluted tubule and inhibits
the Na-Cl cotransport, inducing natriuresis. Prolonged
administration leads to reduction of extracellular fluid
volume with water and sodium reabsorption at the prox-
imal tubules. This leads to reduced water and sodium
delivery to the distal tubules with resultant reduction in
urine output [6]. This theory only partly accounts for
the reduction in urine volume. Animal models have
shown that the thiazide diuretic, hydrochlorothiazide,
also acts at the inner medullary collecting ducts and
enhances water reabsorption by increasing osmotic and
diffusional water permeability. This direct action plays
an important role in reducing urine volume [7]. The
antidiuretic effect of hydrochlorothiazide was more
pronounced with low sodium diet with diminishing of the
effect with high sodium intake [8]. The sum of dietary
nitrogen, sodium, potassium, chloride and phosphorus
determines the solute load to the kidneys, and, there-
fore, the urine osmolality [9]. Urine output increases
proportionately to the renal solute load (RSL) in feedsin the presence of normal renal function and hence low
renal solute feed is used concurrently with thiazides to
reduce urine volume. Breast milk has the lowest renal solute
load and in non-breast fed babies, commercially available
formula with low renal solute load is used (Table 1) [10].
The successful use of thiazide diuretics with low renal
solute load was first documented in a case series of three
infants with central DI [5]. However, transition from
hydrochlorothiazide to desmopressin is warranted with
increasing solid intake. Rivkees et al. has suggested
transition at 12 to 24 months of age when infants are
on at least 80% of solids for their calorie intake [4]. In
the following case series of four newborns with central DI,
we aim to review the efficacy of hydrochlorothiazide and
low renal solute feed in the treatment of central DI by
presenting the clinical response of these infants and
their transition to oral desmopressin.
Methods
The Princess Margaret Hospital Newborn Service is the
sole provider of tertiary neonatal intensive care for Western
Australia. There are approximately 690 admissions per year.
Review of discharge diagnoses over 2007–2013 identified 4
newborns with central DI treated with hydrochlorothiazide.
A retrospective chart review of these patients was con-
ducted to characterize their clinical features and manage-
ment. Diabetes insipidus was diagnosed by the presence of
hypernatremia (sNa > 150 mmol/L), high serum osmolality
(>300 mOsm/L) and low urine osmolality (<300 mOsm/L).
The co-existence of other pituitary hormone deficiencies
was also reviewed.
During the treatment period in which the newborns
were either on desmopressin or hydrochlorothiazide, mean
sNa (SD) and mean change in sNa (SD) per day were
reviewed; the latter was calculated against time, using
sodium measurements taken > 8 hours apart. Episodes
of hyponatremia (sNa <130 mmol/L) and hypernatremia
(sNa >150 mosm/L) were documented. The age of the in-
fant and reason for transition from hydrochlorothiazide to
oral desmopressin was also recorded. Growth parameters
during the first 12 months were assessed.
Informed consent according to Institutional HREC
procedures was obtained from parents for this case
series.
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There were 4 newborns treated for central DI with
thiazide diuretics. DI was secondary to septo-optic dys-
plasia in 3 newborns and to holoprosencephaly in one
newborn. The newborns were born at term with dia-
betes insipidus manifested in the first week of life. In
the three newborns with septo-optic dysplasia, there
were coexistent hormone deficiencies including growth
hormone, thyroxine and cortisol. DI was isolated in the
case (S4) with holoprosencephaly.
Intranasal desmopressin was the first drug instituted
in 2 newborns. Wide fluctuations in sNa levels on des-
mopressin initiated a change to hydrochlorothiazide with
low renal solute load feed and led to stabilisation of sNa
levels. The subsequent 2 newborns with central DI were
commenced on hydrochlorothiazide as the first line drug.
The dose of hydrochlorothiazide was 2 to 3 mg/kg/day in
two divided doses. The diuretic was used in conjunction
with expressed breast milk or commercially available Nan®
H.A. The response to hydrochlorothiazide, with sNa levels
in normal range, was seen within the first 24 hours.
The mean sNa and mean change in sNa (SD) on
treatment with desmopressin and hydrochlorothiazide
are demonstrated in Table 2. sNa levels are more stable
with hydrochlorothiazide. This is demonstrated in the
sNa profile in a newborn with DI (S1) in Figure 1. Transi-
tion to oral desmopressin was initiated at 12 months of
age in two infants when on significant solid intake except
for S2 wherein desmopressin was commenced at 3 months
of age in the background of difficult to control DI with
gastroenteritis. The initial desmopressin doses ranged
from 10 to 50 mcg (Table 3). There was one episode of
symptomatic hyponatremia with intranasal desmopressin
in the neonatal period. Importantly, there were no epi-
sodes of hyponatremia or hypernatremia during the neo-
natal period associated with hydrochlorothiazide and after
transition to oral desmopressin. Other pituitary hormoneTable 2 Mean sNa and mean change in sNa (mmol/L) per day on
(HCT)
S Mean sNa (SD)
Desmopressin Desmopressin (IN)+ HCT+
(IN) HCT Low RSL







+/−2.9deficiencies were carefully monitored and supplemented
in the 3 cases with septo-optic dysplasia.
Discussion
Desmopressin is an effective treatment for central DI;
however the risk of hyponatremia is a significant adverse
effect and reported for all formulations [11]. This case
series demonstrates that hydrochlorothiazide combined
with low solute feed resulted in less variability in sNa
compared to desmopressin therapy in newborns with
central DI and is a safer option in the neonatal period.
Thiazide diuretics are used in the management of
nephrogenic DI [12] and their use has extended to central
DI [5,13] though still not common practice. Chlorothia-
zide was used as the diuretic in a dose of 5 mg/kg every
12 hours and increased urinary osmolality in an infant
with DI from 50 mOsm/L to 100-150 mOsm/L [5]. This
modest increment in urine osmolality is a relatively large
increase considering the limited neonatal renal concen-
trating capacity. Chlorothiazide is not licensed for use in
Australia and hence we used hydrochlorothiazide at a
dose of 3 mg/kg/day as used in nephrogenic DI. The drug
was administered as a suspension (1 ml = 10 mg) formu-
lated in the hospital pharmacy. Although thiazide diuretics
are generally well tolerated in newborns, the clinician
should be aware of the potential risk of hypokalemia
which may occur during episodes of gastroenteritis. We
confirm the observations of Rivkees et al. [3,4] in the case
series presented here that the combined use of hydrochlo-
rothiazide and low renal solute formula feed is effective in
managing central DI whilst the patient is maintained on
a liquid diet. Hydrochlorothiazide was easy to adminis-
ter and did not cause any episode of hyponatremia or
hypernatremia.
By 12 months, most infants have nutritious choices from
the wide variety of foods eaten by the rest of the family [14]
and the renal solute load will vary depending on the proteintreatment with oral desmopressin and hydrochlorothiazide
Mean change in sNa (SD)
Desmopressin Desmopressin (IN)+ HCT+









Figure 1 Serum Na profile in newborn with DI (S1) on intranasal desmopressin and Hydrochlorothiazide (HCT).
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be stable with hydrochlorothiazide therapy as in S1 who
remained on low renal solute formula until one year of
age with supplemental solids. However, she failed to gain
weight although her length was not compromised. Her
growth improved significantly following institution of oral
desmopressin as demonstrated in Figure 2. In S4, the sNa
level was high at 12 months of age as she was on standard
formula with no reduction in volume of feeds with min-
imal solid intake. We infer from both these cases that the
efficacy of hydrochlorothiazide is reduced with increased
renal solute load. It should be noted that growth in S4
remained poor following institution of desmopressin due
to her underlying medical condition (holoprosencephaly)
[15]. Based on our findings from these cases, hypernatre-
mia is a late clinical indicator but transition should be
considered at an early stage of infancy before the infants
are on significant solid intake. Weight loss of 0.8 to 1.5 kgTable 3 Transition from hydrochlorothiazide to oral desmopr
S Etiology Age of transition Reason for transition
1 SOD 12 months Failure to thrive
2 SOD 3 months Acute gastroenteritis with low
K; difficulty in maintaining Na
3 SOD 6 months Failure to thrive




HPE: Holoprosencephaly.was demonstrated in 4 patients (7–17 years) with vasopres-
sin resistant DI when commenced on hydrochlorothiazide
with regain of weight on cessation of the drug [8] which
the authors believe is secondary to the natriuresis induced
by diuretic. Chronic diuretic therapy also causes losses of
potassium, magnesium and zinc and can inhibit protein
synthesis and growth [16].
Intranasal and SC desmopressin have been used in
central DI in infants and recently, there is increasing use
of oral desmopressin. Blanco et al. compared the sNa
profile of 6 infants with SC and 4 infants with intranasal
desmopressin in infants aged less than 12 months of age
and found that SC desmopressin was effective and better
at maintaining sNa in range than intranasal desmopressin
though symptomatic hyponatremia was not observed in
either group [17]. However, symptomatic hyponatremia
with central pontine myelinolysis has been described in a
malnourished 3 year old with holoprosencephaly onessin
Dose of desmopressin F/U: growth
(oral)
50 mcg BD Improved growth
10.5 mcg/kg/
25 mcg BD -NA*-
4.5 mcg/kg/day
10 mcg BD No improvement in growth; concerns
regarding compliance
3.3 mcg/kg/day
50 mcg BD No improvement in growth but growth
impaired due to underlying condition
10 mcg/kg/day
Figure 2 CDC growth chart of S1 demonstrates catch up growth after transition from hydrochlorothiazide (HCT) to oral desmopressin.
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during the newborn period was earlier limited to case
reports as in Table 4 [19-22]. An oral preparation was first
used in view of difficulty with administering intranasal
solutions in a patient with cleft lip/palate [20]. These
first case reports were followed by a case series of
infants with central DI [23]. Oral desmopressin was
commenced at diagnosis (7–300 days) in 11 infants with
central DI with a median initial dose of 2 mcg/kg/day
(0.26 – 18.5). Oral desmopressin was found to be superior
to the intranasal form with less sNa fluctuations and has
been increasingly used as treatment in majority of infants
and toddlers [24]. The dose of desmopressin in infancy
was lower at 1.1 (0.9 – 1.4) mcg/kg/day while the
median oral dose in older children was higher at 9.5 (4.2 –
17.0) mcg/kg/day. Our experience with the use of oral
desmopressin outside the neonatal period has been similar
with doses ranging from 3.3 to 10.5 mcg/kg/day associatedTable 4 Use of oral desmopressin in infants <3 months of age
Case Author Etiology Initial Rx Ag
de
1 Stick [19] Midline defect IN D3
2 Atasay [20] Intracranial haemorrhage IN D7
3 Ozaydin [21] ECP syndrome** Oral < 1
4 Kollamparambil [22] Transient IV 2 m
*NA: not available.
**ECP syndrome: ectrodactyly and cleft lip/palate.with good efficacy and relatively stable sNa levels. In our
centre, oral desmopressin (Minirin 200 mcg) is dissolved
in 20 ml of water and the required dose is administered
with a syringe. This increasing safety and efficacy data
of oral desmopressin supports the early transition to
oral desmopressin.
Conclusion
In conclusion, we report our experience of 4 neonates
with central DI treated with hydrochlorothiazide and
low solute feeds, which supports this as a safe and
effective alternative to desmopressin for treatment of
central DI during the neonatal period. Our results, how-
ever, suggest that hydrochlorothiazide therapy should
be limited to the neonatal and first few months of age.
Transition to desmopressin should occur early during
infancy, at the time of initiation of solid nutrition,
in order to facilitate growth.e of oral
smopressin
Oral dose Oral dose
preparation
3 5 mcg OD increased to BD dose Intranasal solution
3 (5 mcg/day) 2.5 μg/kg/day,
twice daily
Minirin® tablet, 89 μg,
month 2.5 mcg/kg/day, twice daily Minirin® tablet, 89 μg,
onths 4 mcg/day in divided doses -NA*-
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